MedPath
EMA Product

NexoBrid

Product approved by European Medicines Agency (EU)

Basic Information

NexoBrid

Regulatory Information

EMEA/H/C/002246

Authorised

December 18, 2012

September 20, 2012

16

February 1, 2024

Company Information

Germany

MediWound Germany GmbH Hans-Sachs-Strasse 100 65428 Rüsselsheim

Mediwound Germany GmbH

Active Substances Detail

proteolytic enzymes enriched in bromelain

Detailed Information

Therapeutic Indication

### Therapeutic indication NexoBrid is indicated in all age groups for removal of eschar in patients with deep partial- and full-thickness thermal burns.

Overview Summary

NexoBrid is a medicine used for removing eschar (dead tissue which is dried out, thick, leathery and black) due to skin burns caused by heat or fire. It can be used both for deep partial-thickness burns (sometimes called ‘second degree’ burns) which extend into a deep region of an inner layer of the skin called the dermis, and full-thickness burns (sometimes called ‘third degree’ burns) which extend even deeper, through the whole dermis. The active substance in NexoBrid is a concentrate of proteolytic enzymes enriched in bromelain.

© Copyright 2025. All Rights Reserved by MedPath